Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance... Bone Marrow Transplantation (2018) 53:347–351 https://doi.org/10.1038/s41409-017-0054-8 CORRESPONDENCE Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma 1 2 2 3 1 1 ● ● ● ● ● ● Umberto Falcone Haiyan Jiang Shaheena Bashir Richard Tsang Vishal Kukreti Armand Keating 1 1 Michael Crump John Kuruvilla Received: 26 May 2017 / Revised: 28 October 2017 / Accepted: 30 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Mantle cell lymphoma (MCL) is an aggressive B-cell (TBI). Rituximab was approved as part of combination lymphoma accounting for 6–10% of non-Hodgkin lym- chemotherapy for MCL in Ontario in 2003, and RM was phoma, characterized by the chromosomal translocation t approved in 2006. Therefore, rituximab was incorporated (11;14)(q13;q32), de-regulated expression of cyclin D1 [1], into pre- and post-ASCT management at these time points. and median overall survival (OS) of 5–7 years [2]. First-line Before 2006 patients received no maintenance, while after high-dose chemotherapy (HDT) followed by autologous this date, RM was offered to all patients unless contra- stem cell transplant (ASCT) has been reported to improve indicated. MCL diagnosis was confirmed according to patient outcomes [3, 4]. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bone Marrow Transplantation Springer Journals

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma

Loading next page...
 
/lp/springer_journal/effectiveness-and-tolerability-of-first-line-autologous-stem-cell-Xiby9xb1N5
Publisher
Nature Publishing Group UK
Copyright
Copyright © 2017 by The Author(s) 2017, under exclusive licence to Macmillan Publishers Limited, part of Springer Nature
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Cell Biology; Public Health; Hematology; Stem Cells
ISSN
0268-3369
eISSN
1476-5365
D.O.I.
10.1038/s41409-017-0054-8
Publisher site
See Article on Publisher Site

Abstract

Bone Marrow Transplantation (2018) 53:347–351 https://doi.org/10.1038/s41409-017-0054-8 CORRESPONDENCE Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma 1 2 2 3 1 1 ● ● ● ● ● ● Umberto Falcone Haiyan Jiang Shaheena Bashir Richard Tsang Vishal Kukreti Armand Keating 1 1 Michael Crump John Kuruvilla Received: 26 May 2017 / Revised: 28 October 2017 / Accepted: 30 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Mantle cell lymphoma (MCL) is an aggressive B-cell (TBI). Rituximab was approved as part of combination lymphoma accounting for 6–10% of non-Hodgkin lym- chemotherapy for MCL in Ontario in 2003, and RM was phoma, characterized by the chromosomal translocation t approved in 2006. Therefore, rituximab was incorporated (11;14)(q13;q32), de-regulated expression of cyclin D1 [1], into pre- and post-ASCT management at these time points. and median overall survival (OS) of 5–7 years [2]. First-line Before 2006 patients received no maintenance, while after high-dose chemotherapy (HDT) followed by autologous this date, RM was offered to all patients unless contra- stem cell transplant (ASCT) has been reported to improve indicated. MCL diagnosis was confirmed according to patient outcomes [3, 4].

Journal

Bone Marrow TransplantationSpringer Journals

Published: Dec 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off